News

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

Have you used AI in your clinical practice, research, or administration?

A psychiatrist reflects on the importance of time... and living in the moment.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.

Here's how a good online reputation can help clinicians provide a positive patient experience.

“A narrow way through”: can H. Steven Moffic, MD, predict the future of psychiatry?

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

What is new in research on child and adolescent psychiatry?

"We were three men alone in a ward room built for fifty, dust film on the floor..."

Approximately 4 years of COVID-19…

Here’s why ADHD is a diagnosis of exclusion.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

What positivity emerged from the Oscars?

Over these years psychiatry has made strides in the interfaith relationships that can contribute to unity among religious diversity.

More than a gut feeling? Researchers investigated associations between the gut microbiome and treatment resistance in schizophrenia.

"I can smell the aroma of spring tulips filling the air-spreading peace and good cheer..."

These 5 processes provide a focus for patients with PTSD...

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

Using Dune as an indicator of the future of psychiatry…

Check out this case study to learn more about how viral infections might play a role in triggering psychotic disorders.

As we enter the second coming of psychedelics popularity, H. Steven Moffic, MD, looks ahead to their third coming. Will it be similar to that of Dune?

Take a look back at our recent coverage relating to our March content theme.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

New research on transcranial direct current stimulation effectiveness in treating major depressive disorder.

What is new in research on cannabis?

“Advances are made by answering questions. Discoveries are made by questioning answers.”—Bernard Haisch, PhD

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.